Future of the Stem Cell Industry – Exclusive Interviews with Stem Cell Industry Executives

Albany, US, 2018-Apr-07 — /EPR Network/ — Market Research HUB has added a new report titled “Defining the Future of the Stem Cell Industry – Exclusive Interviews with Stem Cell Industry Executives” to its vast collection of market reports. Stem cell research has been in process for over five decades. Stem cells have a unique ability to divide and replicate repeatedly, as well as an “unspecialized” nature that allows them to differentiate into a wide variety of specialized cell types. In a developing embryo, stem cells can differentiate into all of the embryonic tissues. In adult organisms, stem and progenitor cells act as a repair system for the body, replenishing specialized cells.

Request For Sample Report- https://www.marketresearchhub.com/enquiry.php?type=S&repid=1704810

Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into mature cell types. Several broad categories of stem cells exist, including:

• Embryonic stem cells, derived from blastocysts
• Perinatal stem cells, obtained during the period immediately before and after birth
• Adult stem cells, found in adult tissues
• Induced pluripotent stem cells (iPS cells), produced by genetically reprogramming adults cells
• Cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body

The possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells as research tools, to utilization in cell therapies and integration into 3D printed tissues and organs. Additionally, the ability to use stem cells to improve drug target validation and toxicology screening is of intense interest to the pharmaceutical industry.

Rapid Technological Innovation

As a result of this technological innovation, the stem cell industry is undergoing rapid change. As of July 2017, a search for stem cells yields the following results:

• 5,932 Clinical Trials – Search conducted via ClinicalTrials.gov, a global registry of clinical trials that contains approximately 3/4th of trials worldwide, using the terms “stem cell” or “stem cells”
• 45,283 Patents – Search performed using the United State Patent and Trademark Office website, USPTO.gov, using the terms “stem cell” or “stem cells”
• 296,399 Scientific Papers – Search performed on PubMed.gov, a global database of scientific publications maintained by the NIH, using the terms “stem cell” or “stem cells”
• Google Trends identifies that stem cell terms are widely searched in countries worldwide, led by by Singapore, China, UK, USA, and Australia – Google Trends is a service of Google Inc. that identifies how frequently a particular search term is entered relative to total search volume worldwide

Undoubtedly, there is enormous interest surrounding the stem cell industry.  However, this rapid technological changes leaves all industry participants wondering, what will be the future directions for the stem cell industry over the next 5, 10, or 15 years?

Browse Full Report with TOC- https://www.marketresearchhub.com/report/defining-the-future-of-the-stem-cell-industry-exclusive-interviews-with-stem-cell-industry-executives-report.html

Interviews with Stem Cell Industry Executives

Founded in 2006, BioInformant is the first and only market research firm to specialize in the stem cell industry. BioInformant is distinctively suited to tracking the stem cell marketplace, because it has been following the industry for a full decade (2006 to present). This rare attribute provides it with a robust 10-year database of historical information on which to base market predictions.BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine.

For the past decade, BioInformant has been interviewing stem cell industry executives, but this global strategic report represents the first time we have released them in entirety.

BioInformant is honored to launch this 166 page global strategic report featuring dozens of interviews with stem cell industry executives from leading companies worldwide, including the CEO of CDI (KazHirao), CEO of Gamida Cell (Dr Yael Margolin), President and Co-CEO of Pluristem Therapeutics (YakyYanay), and many more.

Within this global strategic report, leading stem cell executives discuss their product development strategies, intellectual property (IP) acquisition plans, manufacturing technologies, strategic collaborations, and much more. If you are competing within the stem cell industry, these insider insights are critical to staying at the forefront of an industry characterized by rapid innovation.